Author:
Sax Paul E.,DeJesus Edwin,Crofoot Gordon,Ward Douglas,Benson Paul,Dretler Robin,Mills Anthony,Brinson Cynthia,Wei Xuelian,Collins Sean E.,Cheng Andrew
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Infectious Diseases,Immunology,Immunology and Allergy
Reference4 articles.
1. Antiviral activity, safety, and pharmacokinetics of bictegravir as 10-day monotherapy in HIV-1-infected adults;Gallant;J Acquir Immune Defic Syndr,2017
2. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled noninferiority trial;Gallant;Lancet,2017
3. Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile;Tsiang;Antimicrob Agents Chemother,2016
4. Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial;Sax;Lancet HIV,2017
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献